Szabolcs Benedek

420 total citations
22 papers, 211 citations indexed

About

Szabolcs Benedek is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Szabolcs Benedek has authored 22 papers receiving a total of 211 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 6 papers in Hematology. Recurrent topics in Szabolcs Benedek's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Glycosylation and Glycoproteins Research (3 papers). Szabolcs Benedek is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Glycosylation and Glycoproteins Research (3 papers). Szabolcs Benedek collaborates with scholars based in Hungary, Slovakia and Sweden. Szabolcs Benedek's co-authors include Maarit Korkeila, Annette Bruchfeld, Henriette Farkas, Lilian Varga, Nóra Veszeli, Károly Cseh, László Kalabay, Dorottya Csuka, Zsuzsanna Zotter and András Kovács and has published in prestigious journals such as European Journal of Cancer, Journal of Clinical Pathology and Nephrology Dialysis Transplantation.

In The Last Decade

Szabolcs Benedek

21 papers receiving 204 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Szabolcs Benedek Hungary 8 69 52 47 44 39 22 211
Véronique Frémeaux-Bacchi France 5 106 1.5× 90 1.7× 33 0.7× 108 2.5× 114 2.9× 7 279
R. Jiji United States 9 98 1.4× 35 0.7× 21 0.4× 70 1.6× 28 0.7× 14 320
E Takeuchi Japan 6 20 0.3× 219 4.2× 35 0.7× 108 2.5× 61 1.6× 26 295
Hagit Hauschner Israel 11 56 0.8× 19 0.4× 17 0.4× 36 0.8× 26 0.7× 27 278
Kiyonobu Ishizuka Japan 8 18 0.3× 158 3.0× 51 1.1× 83 1.9× 32 0.8× 35 253
Shingo Ishimori Japan 13 28 0.4× 142 2.7× 38 0.8× 184 4.2× 24 0.6× 47 392
İbrahim Keser Türkiye 11 66 1.0× 8 0.2× 32 0.7× 108 2.5× 36 0.9× 32 291
Fangrui Ding China 10 24 0.3× 177 3.4× 27 0.6× 121 2.8× 49 1.3× 23 310
Sawsan M. Jalalah Saudi Arabia 8 18 0.3× 92 1.8× 19 0.4× 29 0.7× 12 0.3× 24 168
Irfana Soomro United States 6 66 1.0× 201 3.9× 28 0.6× 105 2.4× 29 0.7× 9 330

Countries citing papers authored by Szabolcs Benedek

Since Specialization
Citations

This map shows the geographic impact of Szabolcs Benedek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Szabolcs Benedek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Szabolcs Benedek more than expected).

Fields of papers citing papers by Szabolcs Benedek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Szabolcs Benedek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Szabolcs Benedek. The network helps show where Szabolcs Benedek may publish in the future.

Co-authorship network of co-authors of Szabolcs Benedek

This figure shows the co-authorship network connecting the top 25 collaborators of Szabolcs Benedek. A scholar is included among the top collaborators of Szabolcs Benedek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Szabolcs Benedek. Szabolcs Benedek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kajdácsi, Erika, et al.. (2023). C1-inhibitor/C1-inhibitor antibody complexes in acquired angioedema due to C1-inhibitor deficiency. Orphanet Journal of Rare Diseases. 18(1). 24–24. 1 indexed citations
3.
Kőhalmi, Kinga Viktória, Nóra Veszeli, Szabolcs Benedek, et al.. (2020). Changes of coagulation parameters during erythema marginatum in patients with hereditary angioedema. International Immunopharmacology. 81. 106293–106293. 7 indexed citations
4.
Wohner, Nikolett, Gergely Varga, Péter Farkas, et al.. (2017). Thalidomidkezelés relabált, diffúz nagy B-sejtes lymphomában idős betegekben. Három eset bemutatása. Orvosi Hetilap. 158(41). 1642–1648. 1 indexed citations
5.
Kőhalmi, Kinga Viktória, Nóra Veszeli, Zsuzsanna Zotter, et al.. (2016). The effect of long-term danazol treatment on haematological parameters in hereditary angioedema. Orphanet Journal of Rare Diseases. 11(1). 7 indexed citations
6.
Veszeli, Nóra, Dorottya Csuka, Zsuzsanna Zotter, et al.. (2015). Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency. Orphanet Journal of Rare Diseases. 10(1). 156–156. 24 indexed citations
7.
Bruchfeld, Annette, et al.. (2013). Rituximab for minimal change disease in adults: long-term follow-up. Nephrology Dialysis Transplantation. 29(4). 851–856. 48 indexed citations
8.
Csomor, Judit, Szabolcs Benedek, János Sinkó, et al.. (2008). Rare provisional entity: primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma in a young woman. Journal of Clinical Pathology. 61(6). 770–772. 6 indexed citations
9.
Benedek, Szabolcs, et al.. (2003). [Severe nephrotic syndrome in a young man taking anabolic steroid and creatine long term].. PubMed. 144(49). 2425–7. 23 indexed citations
10.
Sebestyén, Anna, Ilona Kovalszky, Rudolf Mihalik, et al.. (1997). Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia. European Journal of Cancer. 33(13). 2273–2277. 22 indexed citations
11.
Jánosi, András, et al.. (1995). [Intravascular hemolysis caused by intravenous glycerin infusion in a patient with artificial mitral valve].. PubMed. 136(20). 1055–7. 1 indexed citations
12.
Kalabay, László, Károly Cseh, L Jakab, et al.. (1992). [Diagnostic value of the determination of serum alpha2-HS-glycoprotein].. PubMed. 133(25). 1553–4; 1559. 9 indexed citations
13.
Kalabay, László, Károly Cseh, Szabolcs Benedek, et al.. (1991). Serum α2-HS glycoprotein concentration in patients with hematological malignancies. Annals of Hematology. 63(5). 264–269. 15 indexed citations
14.
Benedek, Szabolcs, et al.. (1988). Bone scanning and radiography in the evaluation of patients with malignant lymphoma.. PubMed. 149(4). 427–8. 3 indexed citations
15.
Heinz, R., et al.. (1987). Initial chemotherapy with an age-adjusted CHOP-schedule in non-Hodgkin lymphomas with unfavorable prognosis. A study of the I.G.C.I.. PubMed. 71(6). 473–9. 6 indexed citations
16.
Cseh, Károly, L Jakab, János Török, et al.. (1985). Fibronectin in cryoimmunoglobulinaemias.. PubMed. 12(6). 483–8. 1 indexed citations
17.
Cseh, Károly, et al.. (1985). Fibronectin on the surface of human lymphocytes. Immunology Letters. 9(6). 301–305. 5 indexed citations
18.
Simón, L, T Jávor, György Deák, et al.. (1984). A comparative dynamic study of the effectiveness of gastric cytoprotection by vitamin A, De-Nol, sucralfate and ulcer healing by pirenzepine in patients with chronic gastric ulcer (a multiclinical and randomized study).. PubMed. 64(3-4). 379–84. 8 indexed citations
19.
Jakab, L, et al.. (1980). Serum proteins in processes associated with an increase in the monoclonal and polyclonal immunoglobulin levels.. PubMed. 37(3). 261–7. 1 indexed citations
20.
Schick, Peter, F. Trepel, Michael Eder, et al.. (1975). Autotransfusion of <sup>3</sup>H-Cytidine-Labelled Blood Lymphocytes in Patients with Hodgkin’s Disease and Non-Hodgkin Patients. Acta Haematologica. 53(4). 206–218. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026